Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study.
Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study. Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Journal of Perinatology. 2022;
Abstract
Objective: To compare short-term respiratory outcomes in preterm infants treated with bovine lipid extract surfactant or poractant alfa.
Study design: Prospective comparative effectiveness cohort study of infants <32 weeks’ gestational age requiring surfactant in thirteen centers. Each center provided bovine lipid extract surfactant for a set period of time in the year 2019 and then changed to poractant alfa for the remainder of the year. The primary outcome was total duration of respiratory support.
Result: 968 infants were included. 494 received bovine lipid extract surfactant and 474 received poractant alfa. No difference was observed in the total duration of respiratory support (mechanical ventilation or non-invasive) (median 38 vs 40.5 days), need to re-dose surfactant, bronchopulmonary dysplasia, survival to discharge, or length of admission.
Conclusion: In this pragmatic study, we did not identify any difference in short-term outcomes between the groups based on the type of surfactant received.
1. Lemyre B, Lacaze-Masmonteil T, Shah PS, Bodani J, Doucette S, Dunn M, et al. Poractant alfa versus bovine lipid extract surfactant: Prospective Comparative Effectiveness Study. Journal of Perinatology. 2022;
More information can be found here: https://pubmed.ncbi.nlm.nih.gov/35177795/
SickKids Paediatric Update Conference 2022
SickKids Paediatric Update Conference – Virtual
SickKids PUC 2022
Thursday, May 4, 2022-Saturday, May 7, 2022
We are excited to be participating in the conference this year and welcome you to check in with us. It will be an excellent opportunity to learn about BLEScath®, our new intratracheal catheter for surfactant administration.
BLEScath® is indicated for the administration of pulmonary surfactant, specifically bovine lipid extract surfactant suspension (BLES®), using less invasive surfactant administration (LISA) technique or minimally invasive surfactant therapy (MIST) for rescue treatment of infants with Neonatal Respiratory Distress Syndrome.
This catheter has an integrated stainless steel stylet that is rigid yet flexible for ease of insertion. The device can be bent and held into the preferred shape providing a balance between maneuverability and procedural success without Magill forceps.
Event Details
For more information, see https://paeds.utoronto.ca/event/PUC2022.
Canadian Paediatric Society Annual Conference 2022
CPS 2022 Annual Conference – Montreal, PQ
Thursday, May 26 – Saturday, May 28, 2022
We are excited to be participating in the conference this year and welcome you to visit us in booth # 27.
It will be an excellent opportunity to learn about BLEScath®, our new intratracheal catheter for surfactant administration.
BLEScath® is indicated for the administration of pulmonary surfactant, specifically bovine lipid extract surfactant suspension (BLES®), using less invasive surfactant administration (LISA) technique or minimally invasive surfactant therapy (MIST) for rescue treatment of infants with Neonatal Respiratory Distress Syndrome.
This catheter has an integrated stainless steel stylet that is rigid yet flexible for ease of insertion. The device can be bent and held into the preferred shape providing a balance between maneuverability and procedural success without Magill forceps.
For more information, see Event Details: https://annualconference.cps.ca/home.
Canadian National Perinatal Research Meeting 2022
CNPRM – Virtual 2022
Monday, May 30 – Friday, June 3, 2022
We are excited to be participating in this year’s conference. We welcome you to join us as we present the “Clinical and Practical Aspects of LISA/Mist” surfactant administration technique. This will also be an excellent opportunity to learn about BLEScath®, our new intratracheal catheter.
BLEScath® is indicated for the administration of pulmonary surfactant, specifically bovine lipid extract surfactant suspension (BLES®), using less invasive surfactant administration (LISA) technique or minimally invasive surfactant therapy (MIST) for rescue treatment of infants with Neonatal Respiratory Distress Syndrome.
This catheter has an integrated stainless steel stylet that is rigid yet flexible for ease of insertion. The device can be bent and held into the preferred shape providing a balance between maneuverability and procedural success without Magill forceps.
For more information, see Event Details https://www.cnprm.ca/.
Canadian Society of Respiratory Therapists 2022
CSRT Annual Conference – Virtual
Friday, May 13, 2022 – Saturday, May 14, 2022
We are excited to be participating in the conference this year and welcome you to check in with us. It will be an excellent opportunity to learn about BLEScath®, our new intratracheal catheter for surfactant administration.
BLEScath® is indicated for the administration of pulmonary surfactant, specifically bovine lipid extract surfactant suspension (BLES®), using less invasive surfactant administration (LISA) technique or minimally invasive surfactant therapy (MIST) for rescue treatment of infants with Neonatal Respiratory Distress Syndrome.
This catheter has an integrated stainless steel stylet that is rigid yet flexible for ease of insertion. The device can be bent and held into the preferred shape providing a balance between maneuverability and procedural success without Magill forceps.
Event Details
For more information, see https://www.csrt.com/conference/